Pfizer: Performance Is Improving, But Secular Issues Persist (Rating Upgrade) Aug. 23, 2024 4:29 AM ET Pfizer Inc. (PFE) Stock , PFE:CA Stock PFE , PFE:CA 17 Comments 3 Likes KM Capital ...

I can sum up Pfizer's (NYSE: PFE) stock performance over the last couple of years in one word (and only three letters): ugh. Shares of the big drugmaker have plunged more than 50% since the high ...

Pfizer's Q1 results showed strong performance in non-COVID products and cost-saving measures. See why PFE stock ... After what happened in NYC vs Trump states have more power over federal issues.

Pfizer reiterated its forecast for 2024 and issued a new one for 2025. Management generally tried to calm some worries from rattled shareholders. There are still a couple of issues to be aware of ...

Pfizer's (NYSE: PFE) share price has fallen more than the S&P 500 so far this year. The big pharma stock is nearly 60% below its high set in late 2022. By most standards, Pfizer looks like the ...

This was the stock's third consecutive day of losses.

Pfizer is now more focused on innovative drugs and vaccines, analyst says Last Updated: Feb. 4, 2025 at 12:58 p.m. ET First Published: Feb. 4, 2025 at 7:09 a.m. ET Share ...

Pfizer's stock performance has been far from thrilling this year, with shares down 3.87% year-to-date. In contrast, the S&P 500 has surged over 21%, making Pfizer look like the laggard of the pack.

Pfizer's trailing-12-month (TTM) revenue is $59.3 billion, whereas its TTM normalized diluted earnings per share (EPS) is $1.55. Per the updated projection for next year, the business anticipates ...